<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01838018</url>
  </required_header>
  <id_info>
    <org_study_id>8777</org_study_id>
    <nct_id>NCT01838018</nct_id>
  </id_info>
  <brief_title>Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN)</brief_title>
  <official_title>Brain Perfusion in Pantothenate Kinase-Associated Neurodegeneration (PKAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susan J. Hayflick</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Clinical and Translational Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn whether blood flow in the brain is normal in people
      with pantothenate kinase-associated neurodegeneration (PKAN). Specifically, preliminary data
      suggest a region of the brain called the globus pallidus (GP), a key region affected by PKAN,
      may have reduced blood flow. Standard MRI and perfusion scanning techniques will be used to
      learn about cerebral blood flow in the globus pallidus and compare it to blood flow in other
      brain regions as well as to healthy controls.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ASL-derived cerebral blood flow(CBF)</measure>
    <time_frame>Single MRI</time_frame>
    <description>The unit of analyses will be the subject and the primary comparison will be the globus pallidus CBF between PKAN and healthy controls.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Pantothenate Kinase-associated Neurodegeneration (PKAN)</condition>
  <arm_group>
    <arm_group_label>PKAN</arm_group_label>
    <description>This group consists of individuals diagnosed with PKAN using a combination of MRI and PANK2 gene sequencing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>This is a control group of healthy volunteers, matched with the PKAN group for age and sex.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The PKAN group consists of individuals in the United States diagnosed with PKAN.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of PKAN confirmed by MRI and gene testing

          -  able to undergo MRI for approximately 1 hour without sedation

        Exclusion Criteria:

          -  deep brain stimulators or other conditions that warrant avoidance of a strong magnetic
             field

          -  previous reaction to gadolinium (Gd) contrast agent

          -  acute or chronic kidney dysfunction

          -  pregnant and/or nursing at time of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan J Hayflick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ohsu.edu/xd/education/schools/school-of-medicine/departments/basic-science-departments/molecular-and-medical-genetics/people/primary-faculty/susan-hayflick.cfm</url>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Susan J. Hayflick</investigator_full_name>
    <investigator_title>Professor &amp; Chair, Molecular &amp; Medical Genetics</investigator_title>
  </responsible_party>
  <keyword>PKAN</keyword>
  <keyword>brain iron</keyword>
  <keyword>NBIA</keyword>
  <keyword>neurodegeneration with brain iron accumulation</keyword>
  <keyword>Hallervorden Spatz Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nerve Degeneration</mesh_term>
    <mesh_term>Pantothenate Kinase-Associated Neurodegeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

